Utah Medical Products (UTMD)
(Delayed Data from NSDQ)
$66.22 USD
-0.11 (-0.17%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $66.21 -0.01 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.22 USD
-0.11 (-0.17%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $66.21 -0.01 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical
by Zacks Equity Research
Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical are included in this Analyst Blog.
Top Analyst Reports for Linde, AstraZeneca & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
by Zacks Equity Research
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
Zacks Initiates Coverage of UTMD With Neutral Recommendation
by Debasmita Chatterjee
Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.
The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace
by Zacks Equity Research
Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace are part of the Zacks top Analyst Blog.
Top Stock Reports for Apple, Mastercard & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).